ClinicalTrials.gg
Not yet recruitingNCT07906457Updated Oct 30, 2026

Effects of Different Bispectral Index Target Depths on Early Postoperative Recovery Quality in Elderly Patients Undergoing Total Knee Arthroplasty

An interventional study of BIS-guided light-depth anesthesia management (BIS target 50-65) and BIS-guided deep-depth anesthesia management (BIS target 35-50) in Total Knee Arthroplasty and Postoperative Recovery, sponsored by General Hospital of Ningxia Medical University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Other

Updated Oct 30, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This is a prospective, single-center, randomized, double-blind controlled trial. The purpose of this study is to determine whether depth-controlled anesthesia with ciprofol guided by Bispectral Index (BIS) can improve early postoperative recovery quality in elderly patients undergoing knee replacement surgery. A total of 130 eligible participants aged 60 years or older will be enrolled.

Participants will be randomly assigned to two groups using block randomization based on the Charlson Comorbidity Index (CCI):

Deep-anesthesia group: general anesthesia maintained with ciprofol targeting a BIS value of 35-50.

Light-anesthesia group: general anesthesia maintained with ciprofol targeting a BIS value of 50-65.

Intraoperative BIS values will be continuously monitored, and ciprofol infusion rates will be adjusted to keep BIS within the target range in each group. Standardized pain management including peripheral nerve blocks and postoperative ultrasound-guided continuous femoral nerve block will be provided for all participants. Blood pressure will be managed following the same protocol in both groups.

The primary outcome is postoperative recovery quality assessed by the Quality of Recovery-15 (QOR-15) questionnaire on the first day after surgery. Investigators will also collect QOR-15 scores on postoperative day 2 and day 3, and record other clinical outcomes including intraoperative hemodynamic events, postoperative delirium, nausea and vomiting, pain level, sleep quality and hospital length of stay. This study aims to compare postoperative recovery between two different BIS-targeted anesthesia depths for older adults receiving joint-replacement surgery.

02

Conditions studied

  • Total Knee Arthroplasty
  • Postoperative Recovery
03

In context

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 110 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective total knee arthroplasty
  • (ASA) physical status classification I-III
  • Aged 60 years or older
  • Able to complete questionnaires
  • Capable of understanding and signing the form

Exclusion criteria

Exclusion Criteria:

  • Patients with a confirmed history of anesthetic drug allergy
  • Pre-existing cognitive dysfunction before surgery
  • Requirement for concurrent surgeries other than knee arthroplasty
  • Patients undergoing bilateral knee arthroplasty, knee revision arthroplasty, or other joint replacement surgeries
  • Severe hepatic dysfunction ( class C or higher)
  • Long-term regular use of benzodiazepines, antidepressants, antipsychotics or other drugs affecting electroencephalographic activity and anesthetic sensitivity
  • Patients with chronic alcohol abuse
  • Patients with language communication disorders or inability to cooperate with follow-up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    deep-depth anesthesia group

    patients receive BIS-guided deep-depth anesthesia with target BIS 35-50 during total knee arthroplasty

    Device: BIS-guided deep-depth anesthesia management (BIS target 35-50)

  • Experimental
    light-depth anesthesia group

    Subjects receive BIS-guided light-depth anesthesia management with target BIS value 50-65 during total knee arthroplasty. All subjects receive standardized anesthesia induction, ultrasound-guided continuous femoral nerve block and uniform hemodynamic management.

    Procedure: BIS-guided light-depth anesthesia management (BIS target 50-65)

Interventions

  • ProcedureBIS-guided light-depth anesthesia management (BIS target 50-65)

    Intraoperative processed electroencephalography (BIS monitor) is used to guide ciprofol infusion to maintain BIS value within 50-65. All subjects receive standardized general-anesthesia induction, ultrasound-guided continuous femoral nerve block for postoperative analgesia, and uniform hemodynamic management.

  • DeviceBIS-guided deep-depth anesthesia management (BIS target 35-50)

    Intraoperative processed electroencephalography (BIS monitor) is used to guide ciprofol infusion to maintain BIS value within 35-50. All subjects receive standardized general-anesthesia induction, ultrasound-guided continuous femoral nerve block for postoperative analgesia, and uniform hemodynamic management.

06

What researchers measure

Primary outcomes

  1. Postoperative Quality of Recovery-15 (QOR-15) score

    The 15-item Quality of Recovery-15 scale assessing postoperative recovery quality, total score ranges from 0 to 150; higher scores indicate better postoperative recovery quality.

    Time frame: postoperative day 1

Secondary outcomes

  1. Quality of Recovery-15 (QOR-15) score

    The 15-item Quality of Recovery Scale (QoR-15). Total score ranges from 0 to 150. Higher scores indicate better postoperative recovery quality.

    Time frame: At postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  2. Incidence of intraoperative awareness assessed by Brice interview

    Intraoperative awareness will be screened using the Brice interview questionnaire

    Time frame: At postoperative day 1, postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  3. Incidence of postoperative delirium assessed by Confusion Assessment Method (CAM)

    Postoperative delirium will be screened using the Confusion Assessment Method (CAM). CAM is a validated tool to identify delirium.

    Time frame: At postoperative day 1, postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  4. Hospital length of stay assessed by medical chart review

    Hospital length of stay is calculated by reviewing electronic medical records

    Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days after randomization

  5. Visual Analog Scale (VAS)-rest pain score

    Visual Analog Scale (VAS) for resting pain. Score ranges from 0 to 10. Higher scores indicate more severe pain.

    Time frame: At postoperative day 1, postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  6. Incidence of postoperative nausea and vomiting (PONV) within postoperative 3 days assessed by clinical observation and medical chart review

    Postoperative nausea and vomiting events are identified through clinical bedside observation and review of electronic medical records.

    Time frame: At postoperative day 1, postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  7. Visual Analog Scale (VAS)-activity pain score

    Visual Analog Scale (VAS) for activity-induced pain. Score ranges from 0 to 10. Higher scores indicate more severe pain.

    Time frame: At postoperative day 1, postoperative day 2 and postoperative day 3, assessed up to 30 days after randomization.

  8. Richard-Campbell Sleep Questionnaire (RCSQ) score

    Richard-Campbell Sleep Questionnaire (RCSQ). Total score ranges from 0 to 100. Higher scores indicate better sleep quality.

    Time frame: At pre-operation, postoperative day 1 and postoperative day 3, assessed up to 30 days after randomization.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2026
First posted
Oct 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Nov 10, 2026
CompletionEst.
Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07906457
Responsible party
Sponsor
First posted
Oct 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Nov 10, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 30, 2026

Study contacts

xinli ni
Contact
xinlini@nyfy.com.cn
18195226033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion